H.C. Wainwright Sees Over 400% Upside For BioCardia Stock

H.C. Wainwright has initiated coverage of BioCardia Inc BCDA with a Buy rating and a $9 price target, suggesting a 414% upside. 

  • Analyst Emanuela Branchetti sees CardiAMP "as an underestimated platform now in the pivotal stage." 
  • BioCardia's CardiAMP Cell Therapy System is designed to provide two autologous bone marrow-derived cell therapies, BCDA-01 and BCDA-02, currently in two pivotal trials targeting heart failure post-myocardial infarction and patients with no option chronic myocardial ischemia with refractory angina.
  • Last week, BioCardia entered into a long-term lease for a new facility in Sunnyvale, California, to provide manufacturing capabilities across its portfolio, including its CardiAMP Cell therapy, NK1R+ mesenchymal stem cells, and biotherapeutic delivery devices.
  • In October, BioCardia treated the first patient in its Phase 3 trial of CardiAMP cell therapy for chronic myocardial ischemia. The trial is expected to enroll up to 343 patients.
  • Price Action: BCDA shares are up 19.4% at $2.09 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechLong IdeasNewsPenny StocksHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!